Elizabeth Thompson, MD, discusses pediatric cancer, proton therapy, and her work as a peer reviewer for CURiE. In an ...

The FDA granted priority review to perioperative durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive disease, based on phase 3 VOLGA data.

Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 ...

Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.

A pooled analysis of the AMY2009 and AMY3001 trials showed daratumumab plus VCd yielded hematologic complete responses in cardiac-involved AL amyloidosis. In the Asian subgroup, the overall ...

Data from the phase 3 LITESPARK-011 trial support the FDA approval of belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma. The FDA has approved belzutifan (Welireg) in ...

Martin T, Usmani S, Berdeja JG, et al. Ciltacabtagene autoleucel in patients with heavily pretreated relapsed/refractory multiple myeloma: 5-year follow-up from CARTITUDE-1. Blood. 2024;144 (suppl ...

Experts preview ASTRO 2026 presentations to watch, including those on SOFT Preop, PSMAgRT, radiosurgery for depression, and AI tools for patient safety.

The FDA has approved lirafugratinib (Lyrfigtu), an investigational oral FGFR2 inhibitor, as a treatment for patients with ...

The panel discussed the risk-benefit profile of the Galleri multicancer early detection test, which was evaluated in the NHS-Galleri and PATHFINDER 2 studies. The executive summary released by the FDA ...

With prostate cancer survival continuing to improve, the long-term cardiovascular consequences of androgen deprivation ...